Ranked #4,981 of 8,699 institutional investors
Aisling Capital Management LP
New York, NY
$298M
US stock portfolio at live prices · today −$3.9M (−1.30%)
Live prices, last trade 11:14 AM ET
- Value at quarter end (Q3 2026)
- $299M
- Change from Q2 2026
- −$172.3M (−36.53%)
- Positions
- 13 · 0 new, 0 sold out
- Filed
- Nov 12, 2026
Not counted in the ranking: none$4.4M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesBBIO 80.2%CMPS 4.72%GLUE 4.56%SNDX 4.00%BCAX 1.66%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| BBIO BridgeBio Pharma, Inc. | 3,089,611 | $239M | 80.2% | Reduced −33% |
| CMPS COMPASS Pathways plc | 1,732,336 | $14.1M | 4.72% | Added +21% |
| GLUE Monte Rosa Therapeutics, Inc. | 1,555,664 | $13.6M | 4.56% | Unchanged |
| SNDX Syndax Pharmaceuticals, Inc. | 1,316,806 | $11.9M | 4.00% | Unchanged |
| BCAX Bicara Therapeutics Inc. | 548,919 | $4.9M | 1.66% | Reduced −4% |
| SRRK Scholar Rock Holding Corporation | 42,031 | $2.1M | 0.72% | Reduced −45% |
| EPRX Eupraxia Pharmaceuticals Inc. | 325,000 | $1.9M | 0.65% | Unchanged |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 1,018,018 | $1.9M | 0.63% | Unchanged |
| ACRS Aclaris Therapeutics, Inc. | 434,455 | $1.5M | 0.51% | Unchanged |
| BMEA Biomea Fusion, Inc. | 2,048,757 | $1.2M | 0.41% | Unchanged |
| VTVT vTv Therapeutics Inc. | 58,775 | $934K | 0.31% | Added +18% |
| MRKR Marker Therapeutics, Inc. | 325,370 | $397K | 0.13% | Unchanged |
| OKUR OnKure Therapeutics, Inc. | 88,607 | $245K | <0.1% | Unchanged |